A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven/NiaStase) in Severely Injured Trauma Patients With Bleeding Refractory to Standard Treatment

Trial Profile

A Multi-centre, Randomised, Double-blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven/NiaStase) in Severely Injured Trauma Patients With Bleeding Refractory to Standard Treatment

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2014

At a glance

  • Drugs Eptacog alfa (Primary)
  • Indications Haemorrhage
  • Focus Registrational; Therapeutic Use
  • Acronyms CONTROL
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 11 Jan 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top